PMID- 36634555
OWN - NLM
STAT- MEDLINE
DCOM- 20230609
LR  - 20230609
IS  - 2590-0412 (Electronic)
IS  - 2590-0412 (Linking)
VI  - 83
DP  - 2023 Jun
TI  - Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage 
      lung cancer with interstitial lung disease (ILD): An observational and 
      exploratory case series of non-asian patients.
PG  - 100984
LID - S2590-0412(22)00099-X [pii]
LID - 10.1016/j.resmer.2022.100984 [doi]
AB  - Interstitial lung disease (ILD) can coexist with early-stage lung cancer (LC) and 
      may compromise surgery and worsen patients' outcomes. Stereotactic body radiation 
      therapy (SBRT) is the gold standard treatment for medically inoperable 
      early-stage lung cancer, but radiation therapy is contra-indicated for patients 
      with ILD because of the higher risk of severe radiation-induced pneumonitis. SBRT 
      may spare healthy lung tissue, but data are scarce in this rare population. Our 
      exploratory case series aimed to retrospectively identify patients treated with 
      SBRT in this setting: 19 patients were diagnosed with early-stage LC-ILD over the 
      past 6 years and 9 received SBRT. Most of them were smokers with a median age of 
      71, 4 had no pathological documentation. After SBRT, 5 patients had grade I-II 
      respiratory adverse events (AEs), but none had treatment-related grade III-IV 
      respiratory AEs. Two patients died within 6 months of SBRT, and for both, death 
      was related to metastatic relapse. In this case series, the radiological 
      evolution of ILD before radiotherapy and the evolution of the radiotherapy scar 
      on CT-Scan were also explored with different evolutionary models. This 
      exploratory study shows available data that could be studied in a larger 
      retrospective cohort to identify risk factors for SBRT in the LC-ILD population. 
      The use of dosimetric data as a risk factor for SBRT should be done with 
      cautiousness due to heterogeneous and complex dose delivery and different 
      fractionation schedule.
CI  - Copyright (c) 2022 SPLF and Elsevier Masson SAS. All rights reserved.
FAU - Pluvy, J
AU  - Pluvy J
AD  - Department of Multidisciplinary Oncology and Therapeutic Innovations Assistance 
      Publique Hopitaux de Marseille AP-HM, Hopital Nord, Marseille, France. Electronic 
      address: johan.pluvy@ap-hm.fr.
FAU - Zaccariotto, A
AU  - Zaccariotto A
AD  - Department of Radiation Oncology, Assistance Publique Hopitaux de Marseille 
      AP-HM, Marseille, France.
FAU - Habert, P
AU  - Habert P
AD  - Radiology Department, Hopital Nord, AP-HM, Aix Marseille Univ, LIIE, CERIMED, 
      Marseille, France.
FAU - Bermudez, J
AU  - Bermudez J
AD  - Department of Respiratory Medicine and Lung Transplantation, Assistance Publique 
      - Hopitaux de Marseille APHM, Hopital Nord, Marseille, Aix -Marseille University, 
      France.
FAU - Mogenet, A
AU  - Mogenet A
AD  - Department of Multidisciplinary Oncology and Therapeutic Innovations Assistance 
      Publique Hopitaux de Marseille AP-HM, Hopital Nord, Aix Marseille University, 
      Marseille, France.
FAU - Gaubert, J Y
AU  - Gaubert JY
AD  - Radiology Department, Hopital Nord, Assistance Publique Hopitaux de Marseille 
      AP-HM, Marseille, France.
FAU - Tomasini, P
AU  - Tomasini P
AD  - Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance 
      Publique Hopitaux de Marseille AP-HM, Aix Marseille University, Marseille, 
      France; Centre de Recherche en Cancerologie de Marseille (CRCM), Inserm UMR1068, 
      CNRS UMR7258, Marseille, France.
FAU - Padovani, L
AU  - Padovani L
AD  - Department of Radiation Oncology, Assistance Publique Hopitaux de Marseille 
      AP-HM, Marseille, France.
FAU - Greillier, L
AU  - Greillier L
AD  - Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille 
      University, APHM, INSERM, CNRS, CRCM, Hopital Nord, Marseille, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20221209
PL  - France
TA  - Respir Med Res
JT  - Respiratory medicine and research
JID - 101746324
SB  - IM
MH  - Humans
MH  - *Lung Neoplasms/complications/epidemiology/radiotherapy
MH  - Retrospective Studies
MH  - *Radiosurgery/adverse effects
MH  - Salvage Therapy
MH  - Neoplasm Recurrence, Local/complications/surgery
MH  - Lung/pathology
MH  - *Lung Diseases, Interstitial/epidemiology/etiology
OTO - NOTNLM
OT  - Carcinoma
OT  - Follow-up studies
OT  - Interstitial lung disease
OT  - Non-small cell lung
OT  - Stereotactic radiation therapy
COIS- Declaration of Competing Interest JP, AZ, PH, JB, AM, GJY, PT, LP, LG nothing to 
      disclose related to the work.
EDAT- 2023/01/13 06:00
MHDA- 2023/06/09 06:42
CRDT- 2023/01/12 18:18
PHST- 2022/05/06 00:00 [received]
PHST- 2022/07/26 00:00 [revised]
PHST- 2022/11/27 00:00 [accepted]
PHST- 2023/06/09 06:42 [medline]
PHST- 2023/01/13 06:00 [pubmed]
PHST- 2023/01/12 18:18 [entrez]
AID - S2590-0412(22)00099-X [pii]
AID - 10.1016/j.resmer.2022.100984 [doi]
PST - ppublish
SO  - Respir Med Res. 2023 Jun;83:100984. doi: 10.1016/j.resmer.2022.100984. Epub 2022 
      Dec 9.